Code of Maine Rules
10 - DEPARTMENT OF HEALTH AND HUMAN SERVICES
144 - DEPARTMENT OF HEALTH AND HUMAN SERVICES - GENERAL
Chapter 104 - MAINE STATE SERVICES MANUAL
Sec2 144-104-8 - Abortion Services for Maine Care Members
Subsection 144-104-8.02 - PROCESS FOR DEVELOPING PROGRAM DESIGN

Universal Citation: 10 ME Code Rules ยง 144-104-8.02

Current through 2024-38, September 18, 2024

In preparation for an application to the federal government, the Department will consult with appropriate federal, other State of Maine agencies, other state officials, and interested parties. It will undertake a process to ensure the development of a program design that is effective, efficient, and practicable, meets state and federal requirements, and achieves the intent of the law. The program elements to be discussed include, but are not limited to:

A. Infrastructure for the importation of the drugs. This includes (but is not limited to):

a. Determining the entities involved in the program domestically and internationally, and the licensing and oversight of them, including the creation of a new licensing pathway, if needed;

b. Evaluating the costs of establishment and ongoing administration of the program, and what fee structure would be necessary to support it;

c. Assessing the willingness of existing actors to participate in the program; and

d. Ensuring the safety of imported drugs.

B. Access to imported drugs. This includes (but is not limited to):

a. How consumers would access the imported prescription drugs;

b. Whether and which employers and / or insurance carriers could access imported prescription drugs; and c. The role of pharmacies and pharmaceutical benefit managers (PBMs) in the program.

C. Identifying the prescription drugs included in the program and a means of updating that list as necessary. This includes (but is not limited to):

a. The potential to achieve "significant savings" relative to current payment rates for specific drugs as required under federal law;

b. Whether the drugs are sole-source, competitive, and / or specialty drugs; and

c. The public health need for lower cost drugs.

D. Establishing an effective and informative process for monitoring and evaluation of the program.

Between January 1st and March 16th, 2020, the Department will provide two avenues for input on the topics above, and other elements of program design as needed:

A. Public meetings hosted and facilitated by the Department, with opportunity for comments and questions from attendees; and

B. A request for information to solicit written comments.

The Department will allow for additional input from stakeholders as necessary after the federal rule is finalized.

Disclaimer: These regulations may not be the most recent version. Maine may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.